| Title: | Effects after starting or switching from bisphosphonate to romosozumab or denosumab in Japanese postmenopausal patients |
| Authors: | Shimizu, Tomohiro Browse this author →KAKEN DB |
| Arita, Kosuke Browse this author |
| Murota, Eihiro Browse this author |
| Hiratsuka, Shigeto Browse this author |
| Fujita, Ryo Browse this author |
| Ishizu, Hotaka Browse this author |
| Asano, Tsuyoshi Browse this author |
| Takahashi, Daisuke Browse this author |
| Takahata, Masahiko Browse this author →KAKEN DB |
| Iwasaki, Norimasa Browse this author →KAKEN DB |
| Keywords: | Postmenopausal osteoporosis |
| Romosozumab |
| Denosumab |
| Bone metabolic marker |
| Issue Date: | Sep-2021 |
| Publisher: | Springer |
| Journal Title: | Journal of Bone and Mineral Metabolism |
| Volume: | 39 |
| Issue: | 5 |
| Start Page: | 868 |
| End Page: | 875 |
| Publisher DOI: | 10.1007/s00774-021-01226-1 |
| Abstract: | Purpose We aimed to investigate the longitudinal changes in bone metabolic markers and bone mineral density (BMD) after starting or switching from bisphosphonate (BP) to romosozumab (ROMO) or denosumab (DENO) therapies over 12 months and to determine predictors that establish associations with changes in BMD among the patients received the ROMO therapy. Methods Postmenopausal osteoporosis patients with a high risk of fracture-154 in total-were recruited; their therapies were switched to ROMO or DENO from BP/naive or vitamin D (ND) (ND-ROMO: 43, BP-ROMO: 38, ND-DENO: 38, and BP-DENO: 35). Longitudinal changes in bone metabolic markers and BMD were evaluated. Results ROMO groups showed significant increases in BMD of the lumbar spine at 6 and 12 months and femoral neck at 12 months compared to the DENO groups. Although BP-ROMO showed significant increase in the lumbar spine BMD compared to BP-DENO, there were no significant differences in femoral neck and total hip BMDs between BP-ROMO and BP-DENO. Among the ROMO groups, % changes of BMD from baseline to 12 months were associated with bone metabolic markers at baseline and changes in TRACP-5b from baseline to 3 months. Conclusions ROMO continuously increased BMD for 12 months and performed better than DENO. On the other hand, effects of ROMO switched from BP on BMD of femoral neck and total hip were almost same with DENO. Bone metabolic markers at baseline and changes in TRACP-5b from baseline to 3 months may predict the efficacy of ROMO after 12 months of administration. |
| Rights: | This is a post-peer-review, pre-copyedit version of an article published in Journal of Bone and Mineral Metabolism. The final authenticated version is available online at: http://dx.doi.org/10.1007/s00774-021-01226-1 |
| Type: | article (author version) |
| URI: | http://hdl.handle.net/2115/86683 |
| Appears in Collections: | 医学院・医学研究院 (Graduate School of Medicine / Faculty of Medicine) > 雑誌発表論文等 (Peer-reviewed Journal Articles, etc)
|
